Bill
SB 1280
SB 1280 enhances consumer protection in the 340B Drug Discount Program by regulating drug pricing, ensuring discounts reach consumers, and promoting transparency.
Bill Number: SB 1280
Title: Relating to Consumer Protection
Status: Referred to CPN/HHS, JDC
Introduced: January 21, 2025
Classification: Bill
Subject: 340B Drug Discount Program, Consumer Protection, Maximum Allowable Cost
SB 1280 aims to enhance consumer protection within the context of the 340B Drug Discount Program. This legislation seeks to address issues related to drug pricing and ensure that consumers benefit from the discounts intended by the program.
The primary intent of SB 1280 is to strengthen consumer protections by regulating the pricing practices associated with the 340B Drug Discount Program. The bill is designed to ensure that the discounts provided under this program are passed on to consumers, thereby reducing their out-of-pocket costs for prescription medications.
Regulation of Maximum Allowable Cost (MAC): The bill proposes to establish guidelines for determining the Maximum Allowable Cost for drugs under the 340B program. This aims to prevent excessive pricing and ensure fair access to discounted medications.
Transparency Requirements: SB 1280 includes provisions that require pharmacies and drug manufacturers to disclose pricing information related to the 340B program. This transparency is intended to empower consumers and healthcare providers to make informed decisions regarding medication purchases.
Consumer Rights Protection: The bill emphasizes the rights of consumers to receive the benefits of the 340B discounts. It aims to prevent practices that could undermine these benefits, ensuring that consumers are not overcharged for medications that should be available at reduced prices.
Consumers: Patients who rely on prescription medications, particularly those eligible for the 340B program, would benefit from the enhanced protections and potential cost savings.
Pharmacies and Drug Manufacturers: Entities involved in the distribution and pricing of drugs under the 340B program will need to comply with the new regulations and transparency requirements set forth in the bill.
Healthcare Providers: Providers who prescribe medications will have clearer information regarding drug pricing, enabling them to better assist their patients in navigating costs.
Legislative Timeline:
Related Legislation: SB 1280 has a companion bill, HB 562, which addresses similar issues in consumer protection related to drug pricing.
SB 1280 represents a significant step towards enhancing consumer protection in the pharmaceutical sector, particularly for those utilizing the 340B Drug Discount Program. By regulating pricing practices and promoting transparency, the bill aims to ensure that consumers receive the intended benefits of drug discounts, ultimately making medications more affordable.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
